GlassScriptPhysician profile
Jessica D Wilson
NPI 1003238338
$2,229.90
in general payments reported to CMS, 2019-2025
23 companies · $58.21 in 2025
The $58.21 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $142 · 2021: $172 · 2022: $681 · 2023: $476 · 2024: $236 · 2025: $58.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.45 | 2021-2025 | Ubrelvy, Qulipta, Viberzi |
| Glaxosmithkline, LLC. | $315.36 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $160.19 | 2023-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $156.55 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $141.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.22 | 2019 | |
| Abbott Laboratories | $107.57 | 2021-2022 | |
| Lilly USA, LLC | $104.82 | 2019-2025 | Mounjaro, Ebglyss, Trulicity |
| Merck Sharp & Dohme LLC | $65.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.06 | 2021-2022 | |
| Pfizer INC. | $53.02 | 2019-2021 | |
| Amgen INC. | $45.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.10 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $31.37 | 2022-2023 | Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $26.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.82 | 2023 | Rexulti |
| Allergan, INC. | $14.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.